Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.07.02.662767

KMT2C and KMT2D regulate skeletal development through stage-specific epigenetic control of chondrogenesis

Abstract

AbstractMany craniofacial disorders linked to mutations in enhancer-associated chromatin-modifying enzymes, including Kabuki syndrome (KS), present with a wide range of skeletal abnormalities. KS is a craniofacial development disorder characterized by mutations in KMT2D, a histone H3 lysine 4 (H3K4) methyltransferase. The KMT2D cellular origins and molecular pathways leading to skeletal deficits in KS are not well characterized. We previously demonstrated that KMT2D deletion in mouse cranial neural crest cells (cNCCs), the multipotent stem cells that contribute to many craniofacial structures, specifically impairs chondrocyte hypertrophic differentiation. Although we observed defects in cNCC endochondral ossification, broader skeletal function of KMT2D is largely unknown and its functional redundancy in skeletal development with its paralog, KMT2C, is understudied. We now find that KMT2D mutation within chondrocyte lineages results in postnatal growth defects and impaired skeletal bone development. We demonstrate redundancy of KMT2C in regulating endochondral ossification as mice lacking both methylases within chondrocyte lineages demonstrate severe deficits in bone formation. These methylases regulate change in chondrocyte state as hypertrophic differentiation is impaired with loss of both KMT2C and KMT2D. When both methylases are deleted in stem cell lineages, KMT2C/KMT2D double mutant cNCCs are unable to properly induce chondrocyte factors downstream of SOX9 activation. At the molecular level, there is a loss of H3K4me1 at de novo chondrocyte enhancers essential for skeletal development and an associated reduction in the efficiency of acetylation with KMT2C/D deficiency, suggesting partial dependency on KMT2C/D presence for appropriate deposition of H3K27ac. We propose a role for KMT2C and KMT2D in facilitating proper activation of genes downstream of SOX9 and RUNX2 transcription factors. Thus, we delineate a regulatory cascade orchestrated by chromatin-level modifications wherein KMT2C/D activity ensures commitment of chondrocyte lineages via enhancer priming. This work not only expands the functional repertoire of COMPASS family members but also defines a chromatin-based mechanism for vertebrate skeletal development, offering insights into the epigenetic basis of skeletal dysplasia and related congenital disorders.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Quickstad, G., Bikas, D. V., Vardabasso, S., Shpargel, K. B.. 2025-07-02. KMT2C and KMT2D regulate skeletal development through stage-specific epigenetic control of chondrogenesis. https://doi.org/10.1101/2025.07.02.662767

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗